PHARMAESSENTIA CORP.
Area: Pharmaceutical and Medical Devices
Booth No: R207
Website: https://hq.pharmaessentia.com/tw
Exhibitor Profile
Compared with similar drugs on the market, the long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for PharmaEssentia’s Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) is granted by EMA in February 2019, Taiwan in May 2020 and FDA in November 2021.
Brands
Ropeginterferon alfa-2b
Exhibit Products
Exhibitors you may be interested in
Highest Rated
-
SUNWAY SCIENTIFIC CORPORATION
-
TAIMED BIOLOGICS INC.
-
EDEN BIOLOGICS, INC., TAIWAN
-
NATIONAL TAIWAN UNIVERSITY
-
THERMO FISHER SCIENTIFIC, PHARMA SERVICES
-
MITEKLAB CO., LTD.
-
ASTRAZENECA TAIWAN LIMITED
-
ALMAC PHARMACEUTICAL SERVICES PTE, LTD.
-
MYCOMAGIC BIOTECHNOLOGY CO., LTD.
-
GOLDEN BIOTECHNOLOGY CORP.
-
BRITISH OFFICE TAIPEI
-
BD (BECTON, DICKINSON HOLDINGS PTE. LTD. TAIWAN BRANCH)
-
COUNCIL OF AGRICULTURE, EXECUTIVE YUAN
-
MOST FORUM
-
TAIPEI MEDICAL UNIVERSITY
-
CHINA MEDICAL UNIVERSITY
-
DEVELOPMENT CENTER FOR BIOTECHNOLOGY
-
BEMER COMPANY LIMITED
-
EIRGENIX INC.
-
MYCENAX BIOTECH INC.
-
NATIONAL YANG MING CHIAO TUNG UNIVERSITY（NYCU GLORIA）
-
AMARAN BIOTECHNOLOGY, INC.
-
RELIANCE BIOSCIENCES INCORPORATED
-
TRADE OFFICE OF SWISS INDUSTRIES
-
IQVIA SOLUTIONS TAIWAN LTD.
-
BRISTOL MYERS SQUIBB (TAIWAN) LTD.
-
GLAXOSMITHKLINE FAR EAST B.V. TAIWAN BRANCH
-
AGRITALK TECHNOLOGY INC.
-
GARAOTUS (SYSTEX GROUP)
-
MEDFLUID CO., LTD.
